Related Experiment Video
Updated: Aug 5, 2026
A Novel in vivo Gene Transfer Technique and in vitro Cell Based Assays for the Study of Bone Loss in Musculoskeletal Disorders
Published on: June 8, 2014
Multi-omics Mendelian randomization integrating RNA-seq, eQTL and pQTL data revealed CPXM1 as a potential drug target
Junxiang Lian1, Xinjian Zhang2, Shanwei Shi1
1Department of Oral and Maxillofacial Surgery, Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, China.
Abstract:
Osteoporosis, a prevalent skeletal disorder characterized by decreased bone mineral density and increased fracture risk, continues to be a major global health concern. Traditional treatments for osteoporosis have limited efficacy and safety profiles, highlighting the need for novel therapeutic targets. This study integrates multi-omics data, including RNA-seq, expression quantitative trait loci (eQTL), and protein quantitative trait loci (pQTL) data, through Mendelian randomization (MR) to identify potential drug targets for osteoporosis. By leveraging bidirectional two-sample MR analysis, we identified CPXM1 (Carboxypeptidase X, M14 family member 1) as a novel gene that is causally linked to osteoporosis risk. Through transcriptomic and proteomic validation, we demonstrate that CPXM1 was upregulated in aged bone tissues and osteoporotic conditions in both human and murine models. Gene set enrichment analysis (GSEA) revealed significant dysregulation of bone homeostasis pathways, including increased extracellular matrix degradation and suppression of osteoblast differentiation in aged mice. Furthermore, phenome-wide association studies (PheWAS) confirmed minimal off-target effects of CPXM1, reinforcing its potential as a therapeutic target. Finally, computational drug repurposing predicted several promising drug candidates, including Doxorubicin, 5-Fluorouracil, and 2-Methylcholine, which may target CPXM1 pathways for osteoporosis treatment. These findings highlight CPXM1 as a potential biomarker and therapeutic target, offering new avenues for osteoporosis therapy.
Insights
This study identifies Carboxypeptidase X, M14 family member 1 (CPXM1) as a novel gene causally linked to osteoporosis risk. CPXM1 upregulation in aged bone suggests it
Area of Science:
- Genetics and Genomics
- Bone Biology
- Pharmacology
Background:
- Osteoporosis is a major global health issue with limited effective treatments.
- Novel therapeutic targets are crucial for managing osteoporosis.
- Current treatments have suboptimal efficacy and safety profiles.
Purpose of the Study:
- To identify novel drug targets for osteoporosis using multi-omics data.
- To investigate the causal relationship between genes and osteoporosis risk.
- To validate potential therapeutic targets through transcriptomic and proteomic analyses.
Main Methods:
- Mendelian randomization (MR) analysis integrating RNA-seq, eQTL, and pQTL data.
- Bidirectional two-sample MR analysis to establish causality.
- Transcriptomic, proteomic, and phenome-wide association studies (PheWAS) for validation.
- Computational drug repurposing for identifying potential treatments.
Main Results:
- Carboxypeptidase X, M14 family member 1 (CPXM1) was identified as a novel gene causally linked to osteoporosis.
- CPXM1 expression was upregulated in aged bone tissues and osteoporotic conditions in human and murine models.
- Dysregulation of bone homeostasis pathways, including extracellular matrix degradation and suppressed osteoblast differentiation, was observed.
- PheWAS indicated minimal off-target effects for CPXM1.
- Drug repurposing identified Doxorubicin, 5-Fluorouracil, and 2-Methylcholine as potential CPXM1-targeting agents.
Conclusions:
- CPXM1 is a promising novel therapeutic target and potential biomarker for osteoporosis.
- Targeting CPXM1 pathways may offer new therapeutic strategies for osteoporosis.
- Further research into CPXM1 and its associated drug candidates is warranted.
More Related Videos
08:27A Non-random Mouse Model for Pharmacological Reactivation of Mecp2 on the Inactive X Chromosome
Published on: May 22, 2019
07:20Author Spotlight: Integrating Traditional Chinese Medicine with Modern Pharmacology and Genomics for Assessing Postmenopausal Osteoporosis in Mice
Published on: August 23, 2024
